Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells that can invade tissues and metastasize to distant organs.
AIG Hospitals Chairman Dr D Nageshwar Reddy stated that AI will augment, not replace, doctors, emphasizing that physicians who use AI will replace those who don't. He highlighted AI's role in drug discovery, diagnostics, and hospital operations, citing examples like MIRA and iSAVE at AIG Hospitals.
FDA granted roxadustat Orphan Drug Designation for myelodysplastic syndromes. The oral HIF-PH inhibitor improved transfusion independence in a Phase 3 post-hoc analysis.
Roche appointed Mark Dawson as Head of Pharma Research and Early Development (pRED), effective 1 May 2026. He will join Roche's Enlarged Corporate Executive Committee. His expertise spans oncology.
Forecasts show the obesity and diabetes drugs market expanding through 2035 on GLP-1 adoption, Europe's HIFU market reaching USD 65.57B by 2033, and AI precision medicine growing at a 31.3% CAGR.
Michelle, a mental health therapist, was diagnosed with stage 4 lung cancer and given 24 months to live. Through yoga and meditation, she shifted her mindset and is now thriving six years after diagnosis, with tumors continuing to shrink.
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
FDA approved iberdomide (Zenbexus) with daratumumab and dexamethasone for pretreated myeloma. The EXCALIBER-RRMM trial showed a 41% MRD-negative complete response rate vs 21%.
Servier agreed to acquire Day One for $2.5B, gaining an approved childhood brain tumor drug and pipeline assets. SCRI and MSD launched a collaboration to expand community oncology trial access, while Recursion took full ownership of REC-102 as Nvidia and Novo exited.
Perspective Therapeutics plans May 2026 analyst event, Q1 results, and conference appearances. The radiopharmaceutical firm is advancing 212Pb-based therapies in Phase 1/2a trials and expanding facilities.
First Ascent Biomedical opened a CLIA- and CAP-certified FPM lab in Miami, testing FDA-approved drugs on patient tumor cells with results in ~10 days. Sponsored testing is available for eligible Florida residents and colorectal cancer patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07816614 |
The Effect of Mandala Coloring on Quality of Life in Cancer Patients |
NOT_YET_RECRUITING | NA |
| NCT07815912 |
Smoking Relapse Prevention in Patients With Cancer |
NOT_YET_RECRUITING | NA |
| NCT07811739 |
Brief Mindfulness Chatbot Intervention for Cancer Patients |
NOT_YET_RECRUITING | NA |
| NCT07811258 |
Improving Adherence to Chronic Disease Medication Regimens Among Patients With Recently Diagnosed Cancer: A Pilot Study |
NOT_YET_RECRUITING | NA |
| NCT07810400 |
A Study Of Remote Patient Monitoring (RPM) Program For Cancer Patients Initiating Cancer-directed Therapy |
NOT_YET_RECRUITING | NA |
| NCT07809386 |
The Effect of Gamified Sleep Hygiene Education on Sleep Quality and Fatigue Levels in Chemotherapy Patients |
NOT_YET_RECRUITING | NA |
| NCT07806760 |
Remote Mindfulness Breathing Training for Patients Undergoing Chemotherapy |
NOT_YET_RECRUITING | NA |
| NCT07806435 |
Evaluation of the Effectiveness of Music Therapy on Anxiety Levels in Patients With Advanced Cancer Hospitalized in a Palliative Care Unit |
NOT_YET_RECRUITING | NA |
| NCT07803289 |
Biomarkers for Cancer Treatment |
RECRUITING | |
| NCT07797608 |
Effect of Progressive Muscle Relaxation on Parental Anxiety |
NOT_YET_RECRUITING | NA |
